Zentek Ltd. (NASDAQ:ZTEK - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 58,700 shares, a decline of 60.3% from the February 28th total of 148,000 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 45,300 shares, the short-interest ratio is currently 1.3 days.
Institutional Trading of Zentek
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC acquired a new stake in Zentek during the fourth quarter worth about $31,000. Scotia Capital Inc. raised its stake in shares of Zentek by 5.7% in the fourth quarter. Scotia Capital Inc. now owns 958,771 shares of the company's stock valued at $867,000 after purchasing an additional 51,744 shares in the last quarter. Finally, Anson Funds Management LP bought a new position in Zentek in the fourth quarter worth $145,000. 0.77% of the stock is currently owned by institutional investors and hedge funds.
Zentek Stock Performance
Shares of NASDAQ ZTEK traded down $0.04 during trading hours on Friday, hitting $1.13. 38,359 shares of the company's stock were exchanged, compared to its average volume of 38,701. The stock has a market capitalization of $117.96 million, a price-to-earnings ratio of -16.14 and a beta of 1.30. The company's 50-day moving average price is $1.06 and its 200-day moving average price is $0.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.83 and a quick ratio of 1.48. Zentek has a 1-year low of $0.50 and a 1-year high of $1.31.
Zentek (NASDAQ:ZTEK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.01) EPS for the quarter. Zentek had a negative return on equity of 58.13% and a negative net margin of 16,555.32%.
Zentek Company Profile
(
Get Free Report)
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.
Featured Articles
Before you consider Zentek, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.
While Zentek currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.